When was Regor founded?

Regor was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Regor located?

Regor is headquartered in Boston, United States.

Who is the current CEO of Regor?

Xiayang Qiu of Regor. They have also founded 1 company.

How many employees does Regor have?

As of Jun 30, 2026, the latest employee count at Regor is 40.

Is Regor a funded company?

Regor is a funded company, having raised a total of $90M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2018.

When was the latest funding round of Regor?

Regor's latest funding was a $***** Series B round on Feb 18, 2021, with participation from 5 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.85B in funding in 2026 to date.

Where does Regor rank among its competitors?

Regor ranks 819th amongst 3568 active competitors, of which 1238 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Regor?

Regor's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Regor - 2026 Company Profile, Team, Funding & Competitors

Q: Is Regor an acquired company?

Regor got acquired by Roche on Sep 30, 2024.

Company Details

Provider of therapeutics related to oncology, autoimmune and metabolic disease. It builds a multi-disciplinary computational platform from structure biology, biopharmaceutics, PK/PD modeling to bioinformatics proactively to stimulate drug discovery from target identification, lead optimization, to clinical Proof of concept.

Website: regor.com
Email ID: *****@regor.com

Key Metrics

Founded Year

2018

Location

Boston, United States

Stage

Acquired

Total Funding

$90M in 2 rounds

Latest Funding Round

Series B, Feb 18, 2021, $*****

Investors

Lilly Asia Ventures & 5 more

Ranked

819^th among 3568 active competitors

Employee Count

40 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3351 more

Exit Details

Acquired by Roche (Sep 30, 2024)

View Regor's full profile

Regor got acquired by Roche on Sep 30, 2024 at an acquisition amount of $*****.

Click here to take a look at Regor's acquisition in detail

Regor has raised a total funding of $90M over 2 rounds. Its first funding round was on 2018. Its latest funding round was a Series B round on Feb 18, 2021 for $*****. 5 investors participated in its latest round. Regor has 6 institutional investors.

Here is the list of recent funding rounds of Regor:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 18, 2021	3332996	Series B	1334627	7198793	7396852	9726792
2018	1237	Seed	5772	2131	Qilu Pharmaceutical Group	7662

Access funding benchmarks and valuations. Sign up today!

View details of Regor's funding rounds and investors

Regor's employee count trend

Regor has 40 employees as of Jun 26. Here is Regor's employee count trend over the years:

Uncover Regor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Regor include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Regor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
819th	Regor 2018, Boston (United States), Acquired	Provider of therapeutics related to oncology, autoimmune and metabolic disease	$90M	TF Capital, Loayal Valley Capital & 4 others	46/100